Skip to main content
Enter your keywords
User account menu
Log in
Main navigation
About
History & Impact
Mission & Values
Leadership
Support SWOG
Join SWOG
Policies & Procedures
Careers
Contact Us
The SWOG Network
How We Work
Our Staff
Our Advocates
Our Partners
News & Events
News
SWOG Stories
SWOG Meetings
For Press
Clinical Trials
Biospecimen Submission
Biospecimen Access
Clinical Trials Search
Clinical Research Resources
Frequently Asked Questions
Publications
Institutions
Quality Assurance & Audits
Serious Adverse Events
Training Resources
CRA Workbench
Protocol Workbench
For Patients
Patient & Advocate Voices
Trials Open to Patients
About SWOG Cancer Trials
Joining a Trial
Glossary
Section navigation
Recent Updates
5/15/2024
5/1/2024
4/15/2024
4/1/2024
3/15/2024
3/1/2024
2/15/2024
2/1/2024
1/15/2024
1/1/2024
12/15/2023
12/1/2023
All Updates
Breadcrumb
SWOG
Member Resources
Trial & Business Updates
Leukemia
Priority List Leukemia
S1925
III
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
S1905
I-II
A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)
CTSU/EA9181
III
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
CTSU/NHLBI-MDS
Other
The National Myelodysplastic Syndromes (MDS) Study
CTSU/A151804
Other
ESTABLISHMENT OF A NATIONAL BIOREPOSITORY TO ADVANCE STUDIES OF IMMUNE-RELATED ADVERSE EVENTS
CTSU/A041501
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
CTSU/A041702
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
CTSU/A041701
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
CTSU/AALL1821
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse
CTSU/A042001
II
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia